New Strong Sell Stocks for March 6th
- ARTL, KW and KRP have been added to the Zacks Rank #5 (Strong Sell) List on March 6, 2025.
- 03/06/2025
|
Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results
- SOLANA BEACH, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the fiscal year ended December 31, 2024.
- 03/03/2025
|
Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®
- SOLANA BEACH, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced nonclinical results on ART12.11, its proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP).
- 02/14/2025
|
Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland
- SOLANA BEACH, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that it will be presenting data on ART12.11, a proprietary cocrystal composed of cannabidiol (CBD) and tetramethylpyrazine (TMP), at the International Medical Cannabis Conference (IMCCB-25) held at the University of Bern, Switzerland February 13-14, 2025.
- 02/11/2025
|
Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12
- The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects Initial safety and pharmacokinetic data expected during the first half 2025 SOLANA BEACH, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, or dermatologic and neurological conditions, today announced the completed safety review of the first cohort of eight healthy volunteers in the Company's Phase 1 study of ART26.12.
- 01/13/2025
|
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia
- Phase 1 data from the CAReS trial showed an attractive safety profile and promising activity from daily ART27.13 administration with two-thirds of participants having stabilized or reversed weight loss at one month of treatment Phase 1 data from the CAReS trial showed an attractive safety profile and promising activity from daily ART27.13 administration with two-thirds of participants having stabilized or reversed weight loss at one month of treatment
- 12/09/2024
|
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit
- SOLANA BEACH, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological and neurological conditions, today announced that Professor Saoirse O'Sullivan, Vice President of Translational Sciences at Artelo, will be presenting at the 7th Cannabinoid-Derived Drug Development Summit. The event will take place November 18-20, 2024, at the Wyndham Beacon Hill Hotel in Boston, MA.
- 11/18/2024
|
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
- ART26.12, the Company's Lead Clinical Fatty Acid Binding Protein 5 Inhibitor, Continues to Show Positive Preclinical Results in Multiple Pain Studies ART26.12, the Company's Lead Clinical Fatty Acid Binding Protein 5 Inhibitor, Continues to Show Positive Preclinical Results in Multiple Pain Studies
- 11/13/2024
|
Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's “Preclinical Screening Platform for Pain” Program
- SOLANA BEACH, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that ART26.12, the Company's lead clinical FABP inhibitor, has been accepted into the NIH Helping to End Addiction Long Term (HEAL) Initiative's Preclinical Screening Platform for Pain (PSPP).
- 11/05/2024
|
Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th
- SOLANA BEACH, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions today announced that it will be participating in the Maxim Group 2024 Virtual Healthcare Summit being held October 15-17, 2024.
- 10/09/2024
|
Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions today announced that Gregory D. Gorgas, CEO of Artelo Biosciences, will be participating in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York City.
- 09/04/2024
|
Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
- SOLANA BEACH, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported its financial and operating results for the three months ended June 30, 2024 and provided a business update.
- 08/13/2024
|
Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor
- ART26.12 seeks to address a critical need in painful neuropathies, including chemotherapy-induced peripheral neuropathy for which there is no FDA-approved treatment
- 07/15/2024
|
Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium
- Multiple studies confirm ART12.11's superior advantages as a product candidate for the treatment of anxiety related disorders Multiple studies confirm ART12.11's superior advantages as a product candidate for the treatment of anxiety related disorders
- 07/03/2024
|
Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society
- ART26.12 shows efficacy in breast cancer-induced bone pain and diabetic neuropathy ART26.12 shows efficacy in breast cancer-induced bone pain and diabetic neuropathy
- 06/04/2024
|
Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24
- ART12.11 demonstrates comparable pharmacokinetics compared to Epidiolex® ART12.11 demonstrates comparable pharmacokinetics compared to Epidiolex®
- 05/29/2024
|
Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
- SOLANA BEACH, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported financial and operating results for the three months ended March 31, 2024 and provided a business update.
- 05/13/2024
|
Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th
- SOLANA BEACH, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that it will be participating in the 2024 Pharma Partnering Summit being held May 14th – 15th in San Diego, California.
- 05/10/2024
|
Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
- Provides Further Evidence of Multiple Opportunities for Development of the FABP Inhibitor Platform in Cancer & Other Serious Conditions Provides Further Evidence of Multiple Opportunities for Development of the FABP Inhibitor Platform in Cancer & Other Serious Conditions
- 04/23/2024
|
Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time
- SOLANA BEACH, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that Gregory D. Gorgas, President and Chief Executive Officer of Artelo, will be a featured guest on the Benzinga All Access show.
- 04/22/2024
|
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
- Major achievements in 2023 lay the foundation for key upcoming milestones Major achievements in 2023 lay the foundation for key upcoming milestones
- 03/25/2024
|
Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge
- ART26.12 Preclinical Dermatology Research Presented to the Immuno-dermatology Leadership Team at Johnson & Johnson ART26.12 Preclinical Dermatology Research Presented to the Immuno-dermatology Leadership Team at Johnson & Johnson
- 03/12/2024
|
Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th
- SOLANA BEACH, CA / ACCESSWIRE / February 15, 2024 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it will be participating in the Winter Wrap-Up MicroCap Rodeo Conference, which will be held virtually Tuesday, February 20th through Friday, February 23rd, 2024. Gregory D.
- 02/15/2024
|
Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
- SOLANA BEACH, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced new research published in the peer-reviewed Journal of Pain. The research article, titled “Discovery and preclinical evaluation of a novel inhibitor of FABP5, ART26.12, effective in Oxaliplatin-induced Peripheral Neuropathy,” highlights Artelo's pre-clinical asset, ART26.12, and its potential ability to treat and prevent Oxaliplatin-Induced Peripheral Neuropathy (OIPN) in a series of separate studies.
- 01/23/2024
|
Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12
- SOLANA BEACH, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it has selected Worldwide Clinical Trials (“Worldwide”), a global award-winning contract research organization (CRO) therapeutically focused on neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory disease, to support the Company's planned Phase 1 trial with ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor in development for the treatment of chemotherapy-induced peripheral neuropathy (CIPN).
- 01/08/2024
|
Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
- ART12.11 demonstrated improved bioavailability of CBD in both the fed and fasted states ART12.11 demonstrated improved bioavailability of CBD in both the fed and fasted states
- 12/05/2023
|
Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
- SOLANA BEACH, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced George Warren, PhD., Principal Scientist at Artelo Biosciences, will be presenting new preclinical data on ART12.11, the Company's proprietary cocrystal of cannabidiol (CBD) and tetremethylpyrazine (TMP), at the 4th Annual Med-Cannabis 2023 conference being held December 4-5, 2023 in Frankfurt, Germany.
- 11/30/2023
|
Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
- $12.9 Million in Cash and Investments as of September 30, 2023; Runway Expected to Reach Meaningful Development Milestones
- 11/13/2023
|
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers
- SOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced new research published in the peer-reviewed journal Pharmaceuticals. The research article, titled “ Cancer-Cachexia-Induced Human Skeletal Muscle Myotube Degeneration is Prevented via Cannabinoid Receptor 2 Agonism in Vitro ,” highlights the promising protective properties of the Company's clinical asset, ART27.13, in helping prevent muscle degeneration caused by cancer.
- 11/09/2023
|
Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023
- SOLANA BEACH, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that the research group working with Steven Laviolette, Ph.D., Scientific Advisor at Artelo Biosciences and Professor in the Schulich School of Medicine at the University of Western Ontario, Canada, will be presenting at Neuroscience 2023. The conference will be hosted by the Society for Neuroscience and held November 11-15, 2023 at the Walter E. Washington Convention Center in Washington, D.C. Neuroscience 2023 is the world's largest source of emerging news on brain science and health, with 25,000 neuroscience researchers and clinicians expected in attendance.
- 11/02/2023
|
Principal Investigator of Artelo's CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia
- SOLANA BEACH, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that H.C. Wainwright will be hosting a virtual medical expert webinar on October 11, 2023 at 12:00 p.m. Eastern Time to discuss the current treatment landscape for cancer-related anorexia and cachexia. The webinar will feature challenges and opportunities from a historical perspective and future strategies including Artelo's lead candidate ART27.13 which is being developed as a supportive care therapy for people suffering from anorexia and weight loss associated with cancer. ARTL27.13 is currently undergoing a Phase 2a clinical trial for this potential indication.
- 10/04/2023
|
Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th
- SOLANA BEACH, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Professor Saoirse O'Sullivan, Artelo's Vice President of Translational Sciences, will be presenting at the 13th Congress of the European Pain Federation (EFIC) being held September 20-22, 2023 at the HUNGEXPO Exhibition Centre in Budapest, Hungary.
- 09/13/2023
|
Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12
- SOLANA BEACH, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced it has completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the manufacturing, preclinical and clinical development plan for ART26.12.
- 09/07/2023
|
Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th
- SOLANA BEACH, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Myles Osborn, Medicinal Chemist at Artelo Biosciences, will be presenting at the 6th Cannabinoid-Derived Drug Development Summit being held September 11-13, 2023 at the Hilton Boston Back Bay hotel in Boston, MA.
- 09/06/2023
|
Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th
- SOLANA BEACH, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.
- 09/05/2023
|
Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
- $14.0 Million in Cash and Investments as of June 30, 2023; Cash Runway Expected to Support Operations into the Second Half of 2024 $14.0 Million in Cash and Investments as of June 30, 2023; Cash Runway Expected to Support Operations into the Second Half of 2024
- 08/10/2023
|
Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023
- New data demonstrates that ART26.12 works by activating multiple receptors implicated in pain signaling and is able to broadly modify lipids in chemotherapy-induced peripheral neuropathy New data demonstrates that ART26.12 works by activating multiple receptors implicated in pain signaling and is able to broadly modify lipids in chemotherapy-induced peripheral neuropathy
- 07/19/2023
|
Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium
- ART12.11, a Novel and Patented Cocrystal of Cannabidiol, Improves Bioavailability and Efficacy of CBD ART12.11, a Novel and Patented Cocrystal of Cannabidiol, Improves Bioavailability and Efficacy of CBD
- 06/07/2023
|
Artelo Biosciences to Present at MicroCap Rodeo's Annual Winter Wonderland – Best Ideas Virtual Investor Conference on February 22, 2023
- SOLANA BEACH, CA / ACCESSWIRE / February 15, 2023 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it has been invited to present at MicroCap Rodeo's Third Annual Winter Wonderland - Best Ideas Virtual Investor conference, which is being held virtually on February 21st - 24th, 2023. Gregory D.
- 02/15/2023
|
Artelo Biosciences to Present at Sequire Biotechnology Conference on February 2nd
- CEO Gregory Gorgas to discuss developments related to the Company's Cancer Appetite Recovery Study (CAReS)
- 01/26/2023
|
Artelo Biosciences to Present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29th
- SOLANA BEACH, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it will be presenting at the 2022 Ladenburg Thalmann Healthcare Conference being held on September 29, 2022 at the Sofitel Hotel in New York City.
- 09/22/2022
|
Artelo Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
- SOLANA BEACH, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Gregory D. Gorgas, Chief Executive Officer of Artelo, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference which is being held September 12 - 14, 2022. The event will include virtual participation as well as in-person participation at the Lotte New York Palace Hotel in New York City.
- 09/07/2022
|
Artelo's (ARTL) FABP5 Inhibitor Effective in Pre-Clinical Study
- Artelo Biosciences (ARTL) reports positive pre-clinical data from one of its FABP5 inhibitors in anxiety-related disorders. Stock up.
- 08/17/2022
|
Artelo Biosciences to Present at the LD Micro Invitational XII on June 7th
- SOLANA BEACH, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL), a clinical-stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer of Artelo, will be presenting at the LD Micro conference which is being held on June 7– 9, 2022, at the Four Seasons Westlake Village, California.
- 06/01/2022
|
Artelo Biosciences to Present at the H.C. Wainwright Global Investment Conference on May 24th
- SOLANA BEACH, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer of Artelo, will be presenting at the H.C. Wainwright Global Investment Conference which is being held on May 23- May 26, 2022 at the Fontainebleau Miami Beach Hotel, Miami FL. The conference will include virtual and in-person participation.
- 05/16/2022
|
Artelo Biosciences to Present at MicroCap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th
- SOLANA BEACH, CA / ACCESSWIRE / May 13, 2022 / Artelo Biosciences, Inc. "Artelo" or the "Company") (NASDAQ:ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer of Artelo has been invited to present at the Spring Into Action - Best Ideas Virtual Investor Conference, which is being held virtually May 16th - 20th, 2022.
- 05/13/2022
|
Artelo Biosciences to Present at Investor Summit Group's Q2 In-Person Conference in New York
- Solana Beach, California--(Newsfile Corp. - April 26, 2022) - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory Gorgas, Chief Executive Officer of Artelo, will present at The Q2 Investor Summit, hosted by the Investor Summit Group, being held on May 3-4, 2022 at The Westin New York Grand Central.Event: The Q2 Investor Summit GroupDate: ...
- 04/26/2022
|
Best Penny Stocks To Buy Now? 7 Stocks Under $1 With Big News Today
- Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy Now?
- 04/13/2022
|
Artelo Biosciences Rounding A Corner With Cannabinoid-Based Therapy
- Over 10 million people are stricken by cancer each year, with as much as 60% suffering from loss of appetite or anorexia and wasting disease or cachexia.
- 03/08/2022
|
Artelo Biosciences Leadership to Participate on Endocannabinoid Panel at the H.C. Wainwright BioConnect 2022 Virtual Conference
- Artelo CEO also providing corporate outlook for 2022 at the H.C. Wainwright Conference Artelo CEO also providing corporate outlook for 2022 at the H.C. Wainwright Conference
- 01/10/2022
|
Is Artelo Biosciences, Inc. (ARTL) Stock Outpacing Its Medical Peers This Year?
- Here is how Artelo Biosciences, Inc. (ARTL) and Avalo Therapeutics, Inc. (AVTX) have performed compared to their sector so far this year.
- 01/06/2022
|
Artelo Biosciences to Present at the Q4 Investor Summit on November 17th
- Solana Beach, California--(Newsfile Corp. - November 11, 2021) - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that management will present at the Q4 Investor Summit, hosted by the Investor Summit Group, being held virtually on November 16-17, 2021.Gregory Gorgas, President and Chief Executive Officer of Artelo Biosciences, is scheduled to present as follows: Ev
- 11/11/2021
|
Best Penny Stocks to Watch in Mid-November 2021
- Are these penny stocks on your watchlist this week? The post Best Penny Stocks to Watch in Mid-November 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 11/07/2021
|
Are These Trending Penny Stocks Worth Buying at Current Levels?
- Check these trending penny stocks out for your watchlist The post Are These Trending Penny Stocks Worth Buying at Current Levels? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 11/05/2021
|
Hot Reddit Penny Stocks to Watch That Exploded Today
- Check these Reddit penny stocks out for your watchlist in November The post Hot Reddit Penny Stocks to Watch That Exploded Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 11/01/2021
|
ARTL Stock: Why The Price Surged Today
- The stock price of Artelo Biosciences Inc (NASDAQ: ARTL) increased by over 60% pre-market today. This is why it happened.
- 11/01/2021
|
Artelo Biosciences, Inc. (ARTL) Q3 2021 Results - Earnings Call Transcript
- Artelo Biosciences, Inc. (ARTL) Q3 2021 Results - Earnings Call Transcript
- 08/18/2021
|
Artelo Biosciences to Present at the Q3 Virtual Investor Summit on August 18th
- Solana Beach, California--(Newsfile Corp. - August 11, 2021) - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, today announced that management will present at the Q3 Virtual Investor Summit, hosted by the Investor Summit Group, being held virtually on August 17-18, 2021.Andrew Yates, PhD, Senior Vice President and Chief Scientific Officer is scheduled to present as follows. Randy...
- 08/11/2021
|
Artelo Biosciences Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines
- Study finds no in-vitro pharmacological difference in the antiproliferative, anti-inflammatory, or permeability effects of purified natural versus synthetic CBD
- 08/04/2021
|
Ladenburg Thalmann to Host R&D Showcase Featuring Artelo Biosciences' CAReS Study on July 28, 2021
- LA JOLLA, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, today announced that Ladenburg Thalmann & Co. Inc. will host an R&D showcase focused on the Phase 1b/2a Cancer Appetite Recovery Study (“CAReS”), evaluating the Company's lead drug candidate, ART27.13. The webinar will be hosted by Michael Higgins, Managing Director and Senior Biopharmaceutical Equity Research Analyst on July 28th, 2021 at 1pm EDT/10am PDT. This event will include the lead investigator on the CAReS study, Barry Laird, PhD, a Senior Clinical Consultant of Palliative Medicine at St Columba's Hospice Care in Edinburg, UK. Among a number of key topics, Dr. Laird will be discussing the etiology of anorexia and the accompanying challenges of effectively treating anorexia.
- 07/21/2021
|
Artelo Biosciences Reports Third Quarter Fiscal 2021 Financial Results and Provides Business Update
- Enrollment in CAReS Study in patients with cancer anorexia on track to deliver first data readout by calendar year-end
- 07/12/2021
|
Relief For Cancer Patients In Artelo Bioscience Pipeline
- Exciting opportunities are emerging for new therapies that target the recently identified endocannabinoid system, which governs numerous cellular processes in human body. To economically build portfolio value, Artelo's business model relies on both in-licensed and internally developed compounds and contracts for clinical services.
- 07/12/2021
|
Artelo Biosciences to Present at the LD Micro Virtual Invitational XI on June 9th
- LA JOLLA, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that management will present at the LD Micro Invitational XI investor conference taking place virtually June 8-10, 2021.
- 06/02/2021
|
Artelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update
- Recently Commenced Patient Enrollment in Phase 1/2 CAReS Study of ART27.13 in the UK
- 04/13/2021
|
Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
- Initial safety data expected from CAReS Study before end of 2021
- 04/12/2021
|
Artelo Biosciences, Inc. (ARTL) CEO Gregory Gorgas Presents at Q1 Virtual Investor Summit Conference (Transcript)
- Artelo Biosciences, Inc. (ARTL) CEO Gregory Gorgas Presents at Q1 Virtual Investor Summit Conference (Transcript)
- 03/23/2021
|
Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development
- Detection of elevated FABP5 associated with additional tumor types suggests the target for ART26.12 may be more broadly relevant in cancer therapy
- 03/19/2021
|
Artelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rd
- LA JOLLA, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory Gorgas, Chief Executive Officer of Artelo Biosciences, will be presenting at the Q1 Virtual Investor Summit.
- 03/11/2021
|
ARTL Stock Price Increases Over 30% Pre-Market: Why It Happened
- The stock price of Artelo Biosciences Inc (NASDAQ: ARTL) has increased by over 30% pre-market. This is why it happened.
- 03/10/2021
|
Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors
- LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appointment of Tamara A. Seymour, CPA, to the Company's board of directors.
- 03/09/2021
|
Artelo Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th
- LA JOLLA, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that Gregory Gorgas, Chief Executive Officer of Artelo Biosciences, will be presenting at the H.C. Wainwright Life Sciences Conference to be held virtually between March 9-10, 2021.
- 03/02/2021
|
Artelo Biosciences Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal
- Research demonstrates co-administration of CBD and TMP could confer ART12.11 with a more desirable pharmacodynamic profile Research demonstrates co-administration of CBD and TMP could confer ART12.11 with a more desirable pharmacodynamic profile
- 02/17/2021
|
ARTL Stock Alert: The Big Reason Biopharma Artelo Biosciences Is Rocketing Today
- Artelo Biosciences (ARTL) stock is soaring higher on Friday after Ladenburg analyst Michael Higgins initiated coverage of the company. The post ARTL Stock Alert: The Big Reason Biopharma Artelo Biosciences Is Rocketing Today appeared first on InvestorPlace.
- 02/12/2021
|
ARTL Stock Price Increases Over 60% Pre-Market: Why It Happened
- The stock price of Artelo Biosciences Inc (NASDAQ: ARTL) is trading at over 60% pre-market today. This is why it happened.
- 02/12/2021
|
Artelo Biosciences Receives $3.0 Million in Net Proceeds from Exercise of Warrants
- LA JOLLA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the exercise of a portion of the warrants from its October 2020 financing. Existing investors agreed to exercise warrants for net proceeds of approximately $3 million.
- 02/08/2021
|
Artelo Biosciences Announces Research Collaboration with Trinity College Dublin to Investigate ART27.13 for the Treatment of Cancer Cachexia
- LA JOLLA, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ) today embarks on a collaboration with researchers from Trinity College Dublin to investigate pre-clinical models of human cancer cachexia, a wasting syndrome that affects up to 80% of all cancer patients and is believed to hasten death in this population.
- 02/02/2021
|
ARTL Stock Price Increases Over 97% Pre-Market: Why It Happened
- The stock price of Artelo Biosciences Inc (NASDAQ: ARTL) has increased by over 97% pre-market. This is why it happened.
- 02/02/2021
|
Artelo Biosciences to Present at the LSX World Congress Virtual Conference
- LA JOLLA, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that it will be presenting at the LSX World Congress to be held virtually between February 1-5, 2021.
- 01/29/2021
|
Artelo Biosciences Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Update
- Received Clinical Trial Authorization to Commence Cancer Appetite Recovery Phase I/II Clinical Study of ART27.13 in UK
- 01/14/2021
|
Artelo Biosciences Files Patent Application for New Formulation of ART27.13
- Expanding the patent estate for the lead clinical program to treat cancer anorexia Expanding the patent estate for the lead clinical program to treat cancer anorexia
- 12/09/2020
|
Artelo Biosciences to Present at The 13th Annual LD Micro Main Event Conference on December 15th
- LA JOLLA, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that it will be presenting at the 13th Annual LD Micro Main Event investor conference on Tuesday, December 15th at 9:40 a.m. PST / 12:40 p.m. EST. Gregory D. Gorgas, Artelo's President and CEO will be presenting to a live, virtual audience.
- 12/08/2020
|
Artelo Biosciences Announces Appointment of Senior Pharmaceutical Executive Gregory R. Reyes, M.D.
- LA JOLLA, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the appointment of drug discovery and development veteran Gregory R. Reyes, M.D., Ph.D. to the Company's Board of Directors, effective November 30, 2020.
- 12/02/2020
|
Artelo Biosciences and University of Western Ontario Awarded Research Grant by Mitacs
- Mitacs Accelerate grant expected to fund 50% of research costs evaluating ART26.12 as a potential treatment for anxiety disorders Mitacs Accelerate grant expected to fund 50% of research costs evaluating ART26.12 as a potential treatment for anxiety disorders
- 11/23/2020
|
Artelo Biosciences Announces Clinical Trial Authorization to Commence Cancer Appetite Recovery Study for the Treatment of Cancer-Related Anorexia and Weight Loss
- First patients on track for enrollment this year
- 11/16/2020
|
Artelo Biosciences Reports Fourth Quarter and Fiscal 2020 Year-End Financial Results and Provides Business Update
- LA JOLLA, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today reported financial and operating results for the fourth quarter and fiscal year ended August 31, 2020 and provided a business update.
- 11/04/2020
|
Artelo Biosciences (ARTL) Investor Presentation - Slideshow
- The following slide deck was published by Artelo Biosciences, Inc. in conjunction with this event..
- 09/03/2020
|
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Avenue Therapeutics Inc (NASDAQ: ATXI)
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI)
DarioHealth Corp (NASDAQ:...
- 08/19/2020
|
Pamela Rothka Named ECS Chief Financial Officer | | IT Business Net
- FAIRFAX, Va.--(BUSINESS WIRE)--#ECS--ECS, a leader in advanced technology, science, and engineering solutions, has named Pamela Rothka to the role of chief financial officer. As a member of the execut
- 08/11/2020
|
Pamela Rothka Named ECS Chief Financial Officer
- ECS has named Pamela Rothka to the role of chief financial officer.
- 08/11/2020
|
CBD, Gut Health, And The Mind
- By Dr. June Chin, Founder of MedLeaf RX and Chief Medical Advisor for Yesterday Wellness.
Have you ever wondered why you have butterflies in your stomach when you are stressed?...
- 08/06/2020
|
LD Micro Announces Preliminary List of Presenters for the LD-500.
- LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
- 08/05/2020
|
Southern California Bancorp Announces Results for the Second Quarter 2020
- Southern California Bancorp (the “Company”) (OTC Pink: BCAL), the holding company for Bank of Southern California, N.A. (the “Bank”) today reported re
- 07/27/2020
|
Artelo Biosciences Reports Q3 Results, Talks Patent For Cocrystal CBD
- Artelo Biosciences (NASDAQ: ARTL) announced its third-quarter results as of May 31.
The La Jolla, California-based company reported a net loss of $951,191,...
- 07/15/2020
|
Artelo Biosciences Reports Third Quarter Fiscal Year 2020 Financial Results and Provides Business Update
- LA JOLLA, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system and related biological signaling pathways, today reported financial and operating results for the third quarter ended May 31, 2020 of its fiscal year ending August 31, 2020 and provided a business update. “We continue to make meaningful clinical and operational progress throughout our therapeutic product candidate pipeline,” stated Gregory D. Gorgas, Artelo’s President and CEO. “Notably, Artelo was awarded the first and only composition of matter patent for our novel cocrystal of CBD, ART12.11, establishing a basis for market exclusivity through the end of 2038 and supporting our development for PTSD and inflammatory bowel disease. Despite delays related to the COVID-19 pandemic, we still expect to receive the appropriate approvals in order to initiate enrollment in our Phase 1b/2a clinical study of ART27.13 for the treatment of cancer-related anorexia later this year.”Artelo recently announced a significant advancement of ART26.12, our Fatty Acid Binding Protein 5 platform, by expanding our license agreement with Stony Brook University to include rights to recently developed compounds supported by a $4.2 million grant from the NCI. With respect to business development, the Company increased discussions with potential partners to help support advancement and provide further validation of its programs.Third Quarter FY2020 Corporate Highlights * Awarded a composition of matter patent from the U.S. Patent and Trademark Office for Artelo’s patent application for ART12.11, the Company’s cocrystal, solid form of CBD. * Conducted multiple investor presentations and business development meetings at well-attended virtual investment conferences. Webcast versions of Artelo’s presentations are available on the Company’s website. Financial Results * Operating expenses for the three months ended May 31, 2020 were $951,395 compared to $941,288 for the same period in 2019. The company’s operating expenses were primarily related to research and development contracts, ongoing regulatory filing requirements, and general and administrative expenses. * Net loss was approximately $951,191, or $0.27 per basic share and fully-diluted share for the quarter ended May 31, 2020 compared to a net loss of $344,883, or $0.17 per basic share and fully-diluted share for the quarter ended May 31, 2019. * As of May 31, 2020, the Company had approximately $1,279,256 in cash, compared to $4,423,965 as of August 31, 2019.About Artelo Biosciences Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system and related biological signaling pathways. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio. Forward Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.Investor Relations Contact: Crescendo Communications, LLC Tel: 212-671-1020 Email: ARTL@crescendo-ir.com
- 07/14/2020
|
The Endocannabinoid System: How Cannabis Interacts With The Body
- This article was originally published on The Cannigma, and appears here with permission.
Discovered by scientists in the early 1990s, the endocannabinoid system is responsible...
- 07/07/2020
|
Artelo Biosciences Expands Stony Brook Commercial License Agreement for FABP5 Platform for Development of Lead Cancer, Pain and Inflammation Compounds
- Artelo Biosciences, Inc. (ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today announced that it has expanded its existing research and worldwide commercial license agreement with The Research Foundation For The State University of New York, Stony Brook. Artelo has obtained exclusive rights to recently developed, third-generation fatty acid binding protein 5 (FABP5) inhibitors. The company plans to select a lead cancer therapeutic compound from these compounds, as well as to identify additional candidates for pain, inflammation and other conditions, facilitating a potentially significant expansion to the company’s development pipeline.
- 06/29/2020
|
Clouds the Likely Cause of Increased Global Warming in Latest Generation of Climate Models
- New representations of clouds are making models more sensitive to carbon dioxide. As scientists work to determine why some of the latest climate models suggest the future could be warmer than previously thought, a new study indicates the reason is likely related to challenges simulating the forma
- 06/27/2020
|
CBD Brand ECS Buys R&D Facility, Equipment From Dean Foods
- ECS Brands recently announced an acquisition of a 10,000 square foot research and development facility formerly occupied by Dean Foods in Broomfield, Colorado.
This deal...
- 06/24/2020
|
Phytocannabinoids & the ECS: Your Top Qs, Answered! | WholeFoods Magazine
- Last year, in our 5th annual deep-dive into the phytocannabinoid market, we explored the research, regulatory issues, legal concerns, and more. It was only 12 months ago, but to say a lot has changed would be an understatement. So this year, we asked the experts to address common questions regarding the current state of the […]
- 06/18/2020
|
Nurturing the ECS: Experts’ Top Tips | WholeFoods Magazine
- There are many ways to support the endocannabinoid system (ECS) beyond supplementation with hemp and CBD. Michael D. Lewis, M.D., of CV Sciences, gives a rundown: “Exercise boosts your endocannabinoid system, and there’s even some evidence that it might be the true mediator of the ‘runner’s high.’ Probiotics can increase the number of cannabinoid receptors […]
- 06/18/2020
|
CJEU Says Copyright Protection May Apply to Product Designs if Technical Result Doesn’t Prevent Creative Choice
- On June 11, the Fifth Chamber of the Court of Justice of the European Union issued a decision holding that European copyright law extends protection to product shapes producing a technical result when the shape is an original work resulting from the author’s intellectual creation.
- 06/18/2020
|
Unlock the Potential of Unstructured Data with DataIQ | Direct2DellEMC
- Data determines the winners and losers in the digital age If we examine the top trends many organizations are focused on today—harnessing big data and
- 06/16/2020
|
Dell updates Isilon with PowerScale label, fresh hardware and other tweaks – Blocks and Files
- Dell has updated its Isilon scale-out filers with new PowerScale branding and products as well as S3 object access and a DataIQ data analytics feature. PowerScale is the brand that Dell deputy chairman Jeff Clarke referred to in comments about the coming Unstructured.NEXT product in the Q1 earnings call in May, calling it “the last …
- 06/16/2020
|
Solutions Architect vs. Developer: An AWS Certification Breakdown
- Which is right for you?
- 06/09/2020
|
American Superconductor Corp. (AMSC) CEO Daniel McGahn on Q4 2020 Results - Earnings Call Transcript
- American Superconductor Corp. (NASDAQ:AMSC) Q4 2020 Results Conference Call June 03, 2020 10:00 AM ET Company Participants John Heilshorn - LHA, IR Daniel McGah
- 06/03/2020
|
Artelo Biosciences to Participate in BIO Digital and The Investor Summit Conferences
- LA JOLLA, Calif., June 03, 2020 -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid.
- 06/03/2020
|
47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th
- NEW YORK, NY / ACCESSWIRE / June 3, 2020 / The Virtual Summer Summit will take place on June 9 th -12 th , connecting 47 presenting small and microcap companies with distinguished investors from around ...
- 06/03/2020
|
The Ultimate AWS Solutions Architect Certification Guide
- Easy peasy lemon squeezy
- 06/03/2020
|
Dell teases PowerScale unified storage array – Blocks and Files
- Dell will launch a unified unstructured storage array line next month, deputy chairman Jeff Clarke said yesterday. In prepared remarks about the company’s Q1 earnings, Clarke revealed: “Next month, Unstructured.NEXT, the last of the powering up of the portfolio, will be delivered.” ‘Powering up’ is a nod to the Power brand prefix that Dell has …
- 05/29/2020
|
The Evolution of the Data Warehouse in the Big Data Era | Direct2DellEMC
- About 20 years ago, I started my journey into data warehousing and business analytics. Over all these years, it’s been interesting to see the evolution of
- 05/28/2020
|
Here's How Cannabis And Cannabinoids Can Help Relieve Anxiety
- By The Fresh Toast's Alana Armstrong, provided exclusively to Benzinga Cannabis.
Cannabis has powerful anxiolytic (anti-anxiety) properties, and when administered as-needed,...
- 05/24/2020
|
ECS Achieves AWS Migration Competency
- ECS, a leader in advanced technology, science, and engineering solutions, has been awarded the Amazon Web Services (AWS) Migration Competency. This award...
- 05/14/2020
|
ECS Achieves AWS Migration Competency
- ECS, a leader in advanced technology, science, and engineering solutions, has been awarded the Amazon Web Services (AWS) Migration Competency. This aw
- 05/14/2020
|
The Era Of Cloud Nomads: Why Multi-Cloud Is Here To Stay
- One of the most effective ways to evolve and future-proof your IT department is to design applications to be nomadic. In time, most organizations will not depend on a single cloud. Here's why.
- 05/13/2020
|
Artelo Biosciences Awarded Composition of Matter Patent for Novel CBD Cocrystal
- Artelo Biosciences, Inc. (ARTL), a clinical stage biopharmaceutical company focused on developing proprietary therapeutics that target the endocannabinoid system and related biological signaling pathways, today announced that the U.S. Patent and Trademark Office has issued a “composition of matter” patent with claims covering ART12.11, the Company’s cocrystal, solid form of CBD (cannabidiol) and TMP (tetramethypyrazine). The new U.S. patent, No. 10,604467 for “Solid Forms of Cannabidiol and Uses Thereof,” provides intellectual property protection for ART12.11 until December 10, 2038. Artelo’s approach to achieving patent protection for a novel CBD composition was to create a cocrystal.
- 05/12/2020
|
Independent Chairperson of the Board Connie Matsui Just Bought 278% More Shares In Artelo Biosciences, Inc. (NASDAQ:ARTL)
- Even if it's not a huge purchase, we think it was good to see that Connie Matsui, the Independent Chairperson of the...
- 05/06/2020
|
Arrow CEO hails shift in focus despite sales drop
- Michael Long says firm faced unprecedented challenges during COVID-19 crisis
- 05/04/2020
|
Unsettled Science: Latest Climate Models Have Unrealistically High Projections of Future Warming
- A new study from University of Michigan climate researchers concludes that some of the latest-generation climate models may be overly sensitive to carbon dioxide increases and therefore project future warming that is unrealistically high. In a letter scheduled for publication April 30 in the jour
- 05/01/2020
|
Channel Steps Up Big to Offer Customer Support During COVID-19 Crisis
- Channel partners are offering customer support during COVID-19 for remote working, cybersecurity services, and even assistance with PPE training.
- 04/28/2020
|
Mental Health Crisis: Stress, Anxiety, Poor Sleep & COVID | WholeFoods Magazine
- Note: The views and opinions expressed here are those of the author(s) and contributor(s) and do not necessarily reflect those of the publisher and editors of WholeFoods Magazine. Information in this article is intended for educational and scientific purposes only. It is not intended as medical or nutritional advice for the treatment or prevention of disease. For […]
- 04/22/2020
|
Artelo Biosciences (NASDAQ:ARTL) versus ExlService (NASDAQ:EXLS) Head to Head Survey
- Artelo Biosciences (NASDAQ:ARTL) and ExlService (NASDAQ:EXLS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings. Earnings and Valuation This table compares Artelo Biosciences and ExlService’s gross revenue, earnings per share and […]
- 04/22/2020
|
Akamai Technologies (NASDAQ:AKAM) & Artelo Biosciences (NASDAQ:ARTL) Head to Head Comparison
- Akamai Technologies (NASDAQ:AKAM) and Artelo Biosciences (NASDAQ:ARTL) are both computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk. Valuation & Earnings This table compares Akamai Technologies and Artelo Biosciences’ top-line revenue, earnings […]
- 04/20/2020
|
Artelo Biosciences Reports Second Quarter Fiscal Year 2020 Financial Results and Provides Business Update
- LA JOLLA, Calif., April 14, 2020 -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate.
- 04/14/2020
|
Does CBD Help Promote Homeostasis? | Ganjapreneur
- The Importance of Homeostasis (The Milieu Interieur) The importance of maintaining your milieu interieur, what is now referred to as… Read More
- 04/09/2020
|
Emergency Cleaning Solutions Equipped and Available for Coronavirus Disinfection
- Emergency Cleaning Solutions Equipped and Available for Coronavirus Disinfection | STL.News | Read press releases and news at STL.News.
- 03/30/2020
|
Artelo Biosciences to Present at the Spring Investor Summit on March 25th
- LA JOLLA, CA / ACCESSWIRE / March 23, 2020 / Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, announced ...
- 03/23/2020
|
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) * BioNTech SE - ADR (NASDAQ: BNTX) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN) ( Updated on its COVID-19 treatment development plan)Down In The
- 03/18/2020
|
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced efforts to develop a vaccine for COVID-19) * SUMMIT THERAPEU/S ADR (NASDAQ: SMMT)Down In The Dumps
- 03/17/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
- 03/13/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Enzo Biochem, Inc. (NYSE: ENZ) * Centogene NV (NASDAQ: CNTG) * Inovio Pharmaceuticals Inc (NASDAQ:
- 03/10/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 9.)
Arcutis...
- 03/10/2020
|
The Spin | European Cricket Series hoping to tap potential from Alicante to Prague
- A new 10-over series beginning this week is hoping to inspire a ‘huge untapped cricket-loving market in mainland Europe’
- 03/03/2020
|
Here's Why We're A Bit Worried About Artelo Biosciences's (NASDAQ:ARTL) Cash Burn Situation
- Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- 03/02/2020
|
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 27) Global Cord Blood Corp (NYSE: CO ) Cleveland BioLabs, ...
- 02/28/2020
|
The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 25) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) (Cowen ...
- 02/26/2020
|
Artelo Biosciences to Present at Biocom’s 10th Annual Global Life Sciences Partnering Conference
- LA JOLLA, Calif., Feb. 24, 2020 -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid.
- 02/24/2020
|
Head-To-Head Comparison: Artelo Biosciences (NASDAQ:ARTL) and Conduent (NASDAQ:CNDT)
- Conduent (NYSE:CNDT) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap business services companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings. Analyst Recommendations This is a breakdown of recent ratings and target prices for Conduent and […]
- 02/23/2020
|
85 Biggest Movers From Yesterday
- Gainers
China Pharma Holdings, Inc. (NYSE: CPHI) shares climbed 96.5% to close at $0.92 on Monday after gaining 11.50% on Friday.
Gulf Resources, Inc. (NASDAQ: GURE) shares...
- 02/04/2020
|
Mid-Afternoon Market Update: NASDAQ Rises Over 1%; Anavex Life Sciences Shares Surge
- Toward the end of trading Monday, the Dow traded up 0.62% to 28,431.07 while the NASDAQ rose 1.28% to 9,267.72. The S&P also rose, gaining 0.87% to 3,253.52.
Leading and...
- 02/03/2020
|
61 Stocks Moving In Monday's Mid-Day Session
- Gainers
China Pharma Holdings, Inc. (NYSE: CPHI) shares jumped 88% to $0.88 after gaining 11.50% on Friday.
Artelo Biosciences, Inc. (NASDAQ: ARTL) shares climbed 50.3% to $3.05...
- 02/03/2020
|
Mid-Day Market Update: Crude Oil Down Over 2%; Insmed Shares Spike Higher
- Midway through trading Monday, the Dow traded up 0.54% to 28408.76 while the NASDAQ rose 1.1% to 9,251.87. The S&P also rose, gaining 0.61% to 3,245.20.
Leading and Lagging...
- 02/03/2020
|
Mid-Morning Market Update: Markets Open Higher; SYSCO Reports Mixed Q2 Results
- Following the market opening Monday, the Dow traded up 1.15% to 28582.23 while the NASDAQ rose 1.37% to 9,276.74. The S&P also rose, gaining 1.08% to 3,260.33.
Leading and...
- 02/03/2020
|
MAXR, AIMT among premarket gainers
- Artelo Biosciences (NASDAQ:ARTL) +63% on NCI grant of $4.2M to Stony Brook University to advance FABP5 inhibitor cancer program.Insmed (NASDAQ:INSM) +48% on positive INS1007 data.CTI BioPharma (NASDAQ
- 02/03/2020
|
Artelo Biosciences Announces NCI Grant of $4.2 Million to Stony Brook University to Advance FABP5 Inhibitor Cancer Program
- Artelo Biosciences, Inc. (ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today announced that the National Cancer Institute (NCI) has awarded Stony Brook University a $4.2 million grant to advance the development of its fatty acid binding protein 5 (FABP5) inhibitor platform. This platform is under exclusive license to Artelo as a potential breakthrough cancer treatment. The five-year grant is intended to support research at Stony Brook University’s Institute of Chemical Biology and Drug Discovery (ICBⅅ), in collaboration with Cold Spring Harbor Laboratory and Artelo Biosciences.
- 02/03/2020
|
Full Spectrum, Broad Spectrum, And Isolate: Meanings And Differences
- By SōRSE Technology staff
The terms full spectrum, broad spectrum, and isolate each refer to types of cannabis extracts known as concentrates. The descriptions indicate the...
- 02/03/2020
|
Artelo Biosciences to Present at the LSX World Congress in London
- LA JOLLA, Calif., Jan. 29, 2020 -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid.
- 01/29/2020
|
CBD and Chronic Pain | Ganjapreneur
- Cannabidiol or CBD, one of the main chemical compounds in cannabis, has been known to help in the treatment of… Read More
- 01/21/2020
|
Artelo Biosciences Reports First Quarter Fiscal Year 2020 Financial Results and Provides Business Update
- LA JOLLA, Calif., Jan. 14, 2020 -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate.
- 01/14/2020
|
Artelo Biosciences Announces Appointment of Seasoned Finance and Industry Executive John W. Beck to Board of Directors
- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today announced the appointment of seasoned industry executive John W. Beck to the Company’s Board of Directors. Mr. Beck brings more than 31 years of financial and strategic operational experience, including 15 years at publicly traded life science companies. Mr. Beck is succeeding Georgia Erbez on the Board of Directors and has been appointed as chair of the audit committee.
- 12/09/2019
|
Artelo Biosciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update
- LA JOLLA, Calif., Nov. 25, 2019 -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate.
- 11/25/2019
|
Omega Support for the Endocannabinoid System | WholeFoods Magazine
- Emerald Health Bioceuticals 5910 Pacific Center Blvd, Suite 300 San Diego, CA 92121 emeraldhealthbio.com Endo Omega Vegan is the first omega supplement physician-formulated to support the endocannabinoid system (ECS) with the essential building blocks needed to produce omega-based endocannabinoids on demand. Winner of the 2019 Nexty Award for Best New Supplement, Endo Omega Vegan provides […]
- 11/21/2019
|
Artelo Biosciences Announces Publication of Positive Non-Clinical Fatty Acid Binding Protein 5 Inhibitor Data in Peer-Reviewed Journal
- Artelo Biosciences, Inc. (ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, announced today that positive non-clinical data with the Company’s Fatty Acid Binding Protein 5 (FABP5) inhibitor program under development in collaboration with The Research Foundation of the State University of New York Stony Brook, were published in the October 2019 issue of The Prostate, a premier peer-reviewed journal.
- 11/18/2019
|
Artelo Biosciences to Present at the Annual Investival Showcase in London
- LA JOLLA, Calif., Nov. 14, 2019 -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid.
- 11/14/2019
|
Artelo Biosciences Announces Selection of Aptus Clinical Ltd. as Clinical Research Organization for Phase 1b/2a Study of ART27.13
- LA JOLLA, Calif., Oct. 29, 2019 -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid.
- 10/29/2019
|
Artelo Biosciences to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
- LA JOLLA, Calif., Oct. 22, 2019 -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid.
- 10/22/2019
|
Hemp, Phytocannabinoids & The Endocannabinoid System: New Perspectives Clinically & Legally! An Interview with Carl Germano, CNS, CDN | WholeFoods Magazine
- Knowledge of the health benefits of cannabinoids appears to be spreading to the general population and many people are asking how cannabinoids work to benefit health. The short answer is that cannabinoids act through the Endocannabinoid System (ECS) to modulate the activity of many organs. If the biological action of cannabinoids is a new subject […]
- 09/26/2019
|
Artelo Biosciences Cannabidiol (CBD) Studies Referenced in September Issue of Nature Medicine
- LA JOLLA, Calif., Sept. 18, 2019 -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the.
- 09/18/2019
|
Artelo Biosciences to Present at the Fall Investor Summit in New York City on September 17th
- LA JOLLA, CA / ACCESSWIRE / September 11, 2019 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid ...
- 09/11/2019
|
What Percentage Of Artelo Biosciences, Inc. (NASDAQ:ARTL) Shares Do Insiders Own?
- A look at the shareholders of Artelo Biosciences, Inc. (NASDAQ:ARTL) can tell us which group is most powerful...
- 09/04/2019
|
CBD Oil Benefits, Tips, & Information | Ganjapreneur
- CBD oil benefits are endless, so the claims say. In this post we dive deeper in to how effective CBD is, how you use it, and more.
- 08/30/2019
|
Accelerating the Dell EMC Partnership with the ‘New’ Cloudera | Direct2DellEMC
- The platform design paradigm from the early days of Hadoop has been to co-locate compute and storage on the same server, which requires expanding both in
- 08/13/2019
|
Product Profiles: Emerald Health Bioceuticals | WholeFoods Magazine
- Powerful Support for the Endocannabinoid System—BEYOND CBD Advanced Support for the Endocannabinoid System Emerald Health Bioceuticals is a global leader in phytocannabinoid science, tapping into nature’s purest and most potent elements to create products that instinctively activate the powerful endocannabinoid system (ECS). Our proprietary, science-backed formulas offer the most advanced, full-spectrum support for endocannabinoid health […]
- 07/18/2019
|
Help Your Customers Focus on Their Data | Direct2DellEMC
- Dell EMC ECS 3.3 software upgrade helps customers unlock value – and helps you protect your revenue and boost your business Sometimes – in business as
- 04/12/2019
|
New Dell EMC ECS Features Help Accelerate and Secure Data-Driven Initiatives with Cloud-Like Capabilities and Lower TCO Than Public Cloud Services | Direct2DellEMC
- Every day we hear of a growing number of enterprises joining the ranks of modern, data-driven organizations. These organizations leverage technology and
- 03/05/2019
|
Apprenticeship will tech the boxes for Scot
- The 22-year-old is working towards a qualification as part of a technical apprenticeship.
- 10/04/2018
|
One Technology Provider for All Your Media Pro Needs | Direct2DellEMC
- We are thrilled to be able to showcase our end-to-end infrastructure and technology solutions at the 2018 NAB Show in Las Vegas, spanning Dell EMC storage, servers and networking, VMware virtualization solutions, and high-performance Dell Precision workstations and displays.
- 04/09/2018
|
Native Hybrid Cloud Makes Waves With Latest Release | Direct2DellEMC
- Less than a year since we announced general availability, Native Hybrid Cloud is quickly becoming the most feature rich way to run cloud-native
- 09/06/2017
|
What is a personal loan? Here's a guide
- Simply put, it is an unsecured loan taken by individuals from a bank or a non-banking financial company (NBFC) to meet their personal needs.
- 01/05/2017
|
Ethan Russi: Endocannabinoid Deficiency| Ganjapreneur
- Read the transcript or listen along as Shango Los interviews Dr. Ethan Russo, renowned cannabis researcher, for The Ganjapreneur Podcast.
- 06/17/2015
|
